Pharmaceutical News

View PDF Net sales up 5%; Medical Devices sales up 7% Second-quarter diluted GAAP earnings per share from continuing operations were $1.01; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.05, up 13% DUBLIN, Apr 27, 2012 (BUSINESS WIRE) --Covidien plc (NYSE: COV) today reported results for the second quarter of fiscal 2012 (January-March 2012). Second-quarter net sales of $2.95 billion increased 5% from the $2.80 billion reported in the second quarter of a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by one percentage point. Second-quarter 2012 gross margin of 57.9% rose 0.9 percentage points fr...

ST. LOUIS--(BUSINESS WIRE)--Apr. 10, 2012-- Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), today joined The Partnership at Drugfree.org in supporting the “Wake Up to Medicine Abuse” campaign. The initiative will address youth prescription medicine abuse and how to prevent it. Announced in conjunction with Operation UNITE’s National Rx Drug Abuse Summit this week in Orlando, Florida, “Wake Up To Medicine Abuse” is a national education effort taking place for the first time September 23-29, 2012. “We must work together to end abuse and illicit diversion of prescription pain medications by inc...

DUBLIN--(BUSINESS WIRE)--Apr. 5, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced a definitive agreement to acquire Oridion Systems Ltd. Oridion Systems (SIX Swiss Exchange: ORIDN), based in Jerusalem, Israel, had 2011 sales of $64 million. The Boards of Directors of both companies have unanimously approved the transaction, pursuant to which a wholly owned subsidiary of Covidien will pay $23.00 in cash per Oridion share for a total of approximately $300 million, net of cash acquired. The ...

MANSFIELD, Mass.--(BUSINESS WIRE)--Apr. 4, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced that it has prevailed against Applied Medical Resources Corp. in a patent action before the U.S. District Court, Central District of California. In granting Covidien’s motion of summary judgment, the District Court ruled that Covidien’s trocar products do not infringe Applied Medical’s patent. In May 2011, Applied Medical sued Covidien in connection with Covidien’s sale of certain trocar products. “We are pleased that the Court recognized that Covidien’s trocar produ...

Properly designed powered surgical staplers may reduce surgeon fatigue and musculoskeletal issues associated with performing minimally invasive surgeries NEW HAVEN, Conn.--(BUSINESS WIRE)--Apr. 3, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that researchers have developed a new method to measure the physical strain placed on surgeons while performing minimally invasive surgery. By analyzing surgeons’ motions in the operating room, researchers will gain new insights into proper postures, techniques and body angles that should influence the development of new erg...

ST. LOUIS--(BUSINESS WIRE)--Mar. 30, 2012-- The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA). The new guidelines, published in the April issue of Arthritis Care & Research, conditionally recommend that healthcare providers consider topical nonsteroidal anti-inflammatory drugs (NSAIDs) as one option for the initial management of knee OA, along with other treatments including acetaminophen, oral NSAIDs, tramadol and intraarticular corticosteroid injections. In addition, the...

Innovative Endomechanical Device Facilitates Insertion, Deployment and Placement of Mesh in Laparoscopic Ventral Hernia Repair NEW YORK--(BUSINESS WIRE)--Mar. 29, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the AccuMesh™ positioning system. This innovative endomechanical device facilitates insertion, deployment and placement of Parietex™ optimized composite (PCOx) mesh during minimally invasive ventral hernia repair procedures. The AccuMesh positioning system adds to Covidien’s comprehensive, evidence-backed hernia care product port...

DUBLIN--(BUSINESS WIRE)--Mar. 26, 2012-- Covidien plc (NYSE: COV) will report second-quarter results on April 27, 2012, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 866-825-1709. For participants outside the U.S., the dial-in number is 617-213-8060...

DUBLIN--(BUSINESS WIRE)--Mar. 22, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced a definitive agreement to acquire Newport Medical Instruments, Inc. Covidien will acquire all of the outstanding capital stock of Newport Medical, which is privately-owned and based in Costa Mesa, CA, for approximately $108 million. The transaction, subject to customary closing conditions, including receipt of certain regulatory approvals, is expected to be completed in the second calendar quarter of 2012. ...

Pain reliever now available for opioid-tolerant patients ST. LOUIS--(BUSINESS WIRE)--Mar. 22, 2012-- Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of its morphine sulfate oral solution for the relief of moderate-to-severe acute and chronic pain in opioid-tolerant patients. The solution is the first generic morphine oral solution to be approved by the U.S. Food and Drug Administration (FDA), and it is available in 100 milligrams per 5 mL (20 milligrams per 1 mL). “Pain is associated with a wide range of injury and...